Our story begins
It all started at Department of physiology, University of Gothenburg in 1971 when Prof KG Rosén, as a young medical student, first discovered the fetus ability to protect the heart in case of asphyxia with anaerobic metabolism and increase in ST waveform of the fetal ECG. It took several decades until technology had advanced far enough to allow the concept to be applied in practice, which was when Neoventa Medical AB was founded in 1997.
KG Rosén was a pioneer within fetal physiology and ST analysis of the fetal ECG, which provides valuable insights that allow clinicians to differentiate between a fetus adapting to a hypoxic environment and one struggling to cope. By properly interpreting these biosignals, you can reduce the occurence of metabolic acidosis and avoid unnecessary procedures, thus optimizing clinical outcomes.
Neoventa Today
Today the Neoventa team consists of 30 employees, spread across our HQ in Mölndal (Sweden), France and UK. All of us are committed to making a positive impact on the future of obstetric care through our fetal monitoring solutions and services.
Join us in our quest to make a difference, where innovation meets compassion and where every day brings us closer to a world with happier beginnings.
Quality & Certification
Our company meets the requirements of:
MDSAP
MDR 2017/745
ISO 13485
Our mission and vision
Vision
A safe delivery for every child and mother.
Mission
Develop and provide solutions, products and knowledge that will help clinicians in their work to improve obstetric care.
References
Amer-Wåhlin I, Ugwumadu A, Yli BM, Kwee A, Timonen S, Cole V, Ayres-de-Campos D, Roth GE, Schwarz C, Ramenghi LA, Todros T, Ehlinger V, Vayssiere C; Study Group of Intrapartum Fetal Monitoring (European Association of Perinatal Medicine). Fetal electrocardiography ST-segment analysis for intrapartum monitoring: a critical appraisal of conflicting evidence and a way forward. Am J Obstet Gynecol. 2019 Dec;221(6):577-601.e11. doi: 10.1016/j.ajog.2019.04.003.